Skip to content

13F-HR filed by Octagon Capital Advisors LP

Octagon Capital Advisors LP filed this 13F-HR for the quarter ended 2021-09-30, filed 2021-11-15, with 30 holding rows worth $406,144,000.

Accession
0001214659-21-011794
Filed
2021-11-15
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2021

A holdings report, 30 entries on the cover page, a total value of $406,144,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $406,144,000 with VALUE read as thousands by filing date, 13F file number 028-20958. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
NOVABRIDGE BIOSCIENCES44975P103CMN764,461$55,416,000thousands by filing date
APELLIS PHARMACEUTICALS INC03753U106COM1,595,911$52,601,000thousands by filing date
CELLDEX THERAPEUTICS INC NEW15117B202COM NEW761,398$41,108,000thousands by filing date
ARCUS BIOSCIENCES INC03969F109COM970,164$33,830,000thousands by filing date
BRIDGEBIO PHARMA INC10806X102COM569,414$26,688,000thousands by filing date
4D MOLECULAR THERAPEUTICS INC COM35104E100Stock831,267$22,419,000thousands by filing date
GOSSAMER BIO INC COM38341P102Stock1,513,138$19,020,000thousands by filing date
CURIS INC231269200COM2,294,721$17,968,000thousands by filing date
CENTURY THERAPEUTICS INC15673T100COM602,623$15,162,000thousands by filing date
ARVINAS INC04335A105COM168,500$13,847,000thousands by filing date
VERA THERAPEUTICS INC92337R101COMMON STOCK696,126$12,078,000thousands by filing date
AVIDITY BIOSCIENCES INC COM05370A108Stock446,641$11,001,000thousands by filing date
CYTEK BIOSCIENCES INC23285D109COMMON STOCK500,000$10,705,000thousands by filing date
DYNE THERAPEUTICS INC COM26818M108Stock583,649$9,478,000thousands by filing date
CONNECT BIOPHARMA HLDGS LTD207523101SHS326,143$7,795,000thousands by filing date
STOKE THERAPEUTICS INC86150R107COM296,822$7,551,000thousands by filing date
OMEGA THERAPEUTICS INC68217N105COMMON STOCK370,279$6,980,000thousands by filing date
CARDIFF ONCOLOGY INC14147L108COM982,753$6,545,000thousands by filing date
PROMETHEUS BIOSCIENCES INC74349U108COM200,000$4,742,000thousands by filing date
AMBRX BIOPHARMA, INC. SPONSORED ADR02290A102COM350,000$4,725,000thousands by filing date
IVERIC BIO INC46583P102COM277,057$4,499,000thousands by filing date
NGM BIOPHARMACEUTICALS INC62921N105COM200,000$4,204,000thousands by filing date
MOONLAKE IMMUNOTHERAPEUTICSG4444C102COM400,000$3,948,000thousands by filing date
IKENA ONCOLOGY INC45175G108COM275,000$3,471,000thousands by filing date
MONTE ROSA THERAPEUTICS INC61225M102COM150,000$3,342,000thousands by filing date
PMV PHARMACEUTICALS INC69353Y103COM100,141$2,984,000thousands by filing date
JIYA ACQUISITION CORP47760M102CMN300,000$2,934,000thousands by filing date
EDGEWISE THERAPEUTICS INC28036F105COM50,000$830,000thousands by filing date
DESIGN THERAPEUTICS INC25056L103COM14,926$219,000thousands by filing date
TENAX THERAPEUTICS INC88032L209COM30,600$54,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001214659-21-011794this filing2021-11-15acceptance time not in the bulk data set